{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:34:47Z","timestamp":1790480087090,"version":"4.1.0"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:00:00Z","timestamp":1526428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0197302","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T17:48:56Z","timestamp":1526492936000},"page":"e0197302","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Stopping the effective non-fluoroquinolone antibiotics at day 7 vs continuing until day 14 in adults with acute pyelonephritis requiring hospitalization: A randomized non-inferiority trial"],"prefix":"10.1371","volume":"13","author":[{"given":"Pavankumar","family":"Rudrabhatla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2151-4273","authenticated-orcid":true,"given":"Surendran","family":"Deepanjali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jharna","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rathinam Palamalai","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamilarasu","family":"Kadhiravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/520427","article-title":"Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women","volume":"29","author":"JW Warren","year":"1999","journal-title":"Infectious Diseases Society of America (IDSA). Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/AOG.0b013e318169f6ef","article-title":"ACOG Practice Bulletin No. 91: Treatment of urinary tract infections in nonpregnant women","volume":"111","year":"2008","journal-title":"Obstet Gynecol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"K Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial","volume":"283","author":"DA Talan","year":"2000","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"J Peterson","year":"2008","journal-title":"Urology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijantimicag.2016.01.008","article-title":"Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010\u20132013","volume":"47","author":"SS Jean","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40121-015-0095-5","article-title":"Antimicrobial Resistance of Escherichia coli Causing Uncomplicated Urinary Tract Infections: A European Update for 2014 and Comparison with 2000 and 2008","volume":"4","author":"G Kahlmeter","year":"2015","journal-title":"Infect Dis Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1874285801206010074","article-title":"Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009\u20132010","volume":"6","author":"S Bouchillon","year":"2012","journal-title":"Open Microbiol J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3201\/eid2209.160148","article-title":"EMERGEncy ID Net Study Group. Fluoroquinolone-resistant and extended-spectrum \u03b2-lactamase\u2013producing Escherichia coli infections in patients with pyelonephritis, United States","volume":"22","author":"DA Talan","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e02236","DOI":"10.1128\/AAC.02236-16","article-title":"Antimicrobial resistance of Escherichia coli urinary isolates in the Veterans Affairs health care system","volume":"61","author":"HJ Morrill","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jinf.2011.05.015","article-title":"Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region","volume":"63","author":"PR Hsueh","year":"2011","journal-title":"J Infect"},{"key":"ref12","unstructured":"National Centre for Disease Control. Directorate General of Health Services. Ministry of Health & Family Welfare. Government of India. National Treatment Guidelines for Antimicrobial Use in Infectious Diseases Version 1.0; 2016 [cited 2018 February 17]. Available from: http:\/\/pbhealth.gov.in\/AMR_guideline7001495889.pdf<\/ext-link>."},{"key":"ref13","unstructured":"Indian Council of Medical Research, Department of Health Research New Delhi, India. Treatment Guidelines for Antimicrobial Use in Common Syndromes; 2017 [cited 2018 February 17] Available from: http:\/\/www.icmr.nic.in\/guidelines\/treatment%20guidelines%20for%20antimicrobial.pdf<\/ext-link>"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF01973737","article-title":"Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis","volume":"9","author":"T Sandberg","year":"1990","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/1120009X.1991.11739124","article-title":"A comparative study on aztreonam, ceftazidime and amikacin in the treatment of complicated urinary tract infections","volume":"3","author":"MD Melekos","year":"1991","journal-title":"J Chemother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/BF01704892","article-title":"Open, randomized comparison of pefloxacin and cefotaxime in the treatment of complicated urinary tract infections","volume":"20","author":"C Timmerman","year":"1992","journal-title":"Infection"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMcp1702758","article-title":"Acute pyelonephritis in adults","volume":"378","author":"JR Johnson","year":"2018","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/infdis\/163.2.325","article-title":"Therapy for women hospitalized with acute pyelonephritis: a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days","volume":"163","author":"JR Johnson","year":"1991","journal-title":"J Infect Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e00473","DOI":"10.1128\/AAC.00473-17","article-title":"the SATURN Diagnostic Study Group. Amplification of antimicrobial resistance in gut flora of patients treated with ceftriaxone","volume":"61","author":"J Meletiadis","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","first-page":"842","article-title":"Antibiotic resistance pattern among common bacterial uropathogens with a special reference to ciprofloxacin resistant Escherichia coli","volume":"136","author":"J Mandal","year":"2012","journal-title":"Indian J Med Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/bmj.330.7495.843","article-title":"Treatment allocation by minimisation","volume":"330","author":"DG Altman","year":"2005","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"734","DOI":"10.4236\/jbise.2011.411090","article-title":"Implementation of an open-source customizable minimization program for allocation of patients to parallel groups in clinical trials","volume":"4","author":"M Saghaei","year":"2011","journal-title":"J Biomed Sci Eng"},{"key":"ref23","unstructured":"World Health Organization. Anatomical Therapeutic Chemical (ATC) Classification System: Guidelines for ATC Classification and DDD Assignment 2013: WHO Collaborating Centre for Drug Statistics Methodology; 2013 [cited 2018 February 17] Available from: https:\/\/www.whocc.no\/filearchive\/publications\/1_2013guidelines.pdf<\/ext-link>"},{"key":"ref24","unstructured":"Sealed Envelope Ltd. Power calculator for binary outcome non-inferiority trial; 2012 [cited 2018 February 17]. Available from: https:\/\/www.sealedenvelope.com\/power\/binary-noninferior\/<\/ext-link>"},{"key":"ref25","unstructured":"Food and Drug Administration, U.S. Department of Health and Human Services. Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry; 2015 [cited 2018 February 17]. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070981.pdf<\/ext-link>"},{"key":"ref26","unstructured":"Infectious Diseases Society of America. IDSA comments on FDA draft guidance for developing cUTI drugs; 2012 [cited 2018 February 17]. Available from: https:\/\/www.idsociety.org\/uploadedFiles\/IDSA\/Policy_and_Advocacy\/Current_Topics_and_Issues\/Advancing_Product_Research_and_Development\/Bad_Bugs_No_Drugs\/Position_Papers\/IDSA%20Comments%20on%20cUTI%20Draft%20Guidance%20052412.pdf<\/ext-link>"},{"key":"ref27","first-page":"CD003543","article-title":"Interventions to improve antibiotic prescribing practices for hospital inpatients","volume":"4","author":"P Davey","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1128\/AAC.01257-13","article-title":"Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection","volume":"57","author":"KP Singh","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","unstructured":"Tandberg D. Improved confidence intervals for the difference between two proportions and number needed to treat (NNT). Version 1.49; 2014 [cited 2018 February 17]. Available from: www.cebm.net\/wp-content\/uploads\/2014\/04\/Diff2PropCI49.xls<\/ext-link>"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/0003-4819-107-2-430_1","article-title":"Treatment of acute urinary tract infection in women","volume":"107","author":"RR Bailey","year":"1987","journal-title":"Ann Intern Med"},{"key":"ref31","first-page":"102","article-title":"Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis","volume":"105","author":"RR Bailey","year":"1992","journal-title":"N Z Med J"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkm193","article-title":"Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"L Vidal","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1186\/cc10545","article-title":"Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis","volume":"15","author":"TC Havey","year":"2011","journal-title":"Crit Care"},{"issue":"Suppl 2","key":"ref34","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"LA Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","article-title":"Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial","volume":"380","author":"T Sandberg","year":"2012","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11908-011-0211-y","article-title":"Treatment duration of febrile urinary tract infections","volume":"13","author":"WE van der Starre","year":"2011","journal-title":"Curr Infect Dis Rep"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/jac\/dkt177","article-title":"Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection\u20147 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials","volume":"68","author":"N Eliakim-Raz","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/1120009X.2017.1380395","article-title":"Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review","volume":"29","author":"A Mazzariol","year":"2017","journal-title":"J Chemother"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials","volume":"72","author":"MW Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1128\/AAC.00837-08","article-title":"Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis","volume":"53","author":"KG Naber","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/jac\/dku215","article-title":"The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"69","author":"SH Park","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3904\/kjim.2016.31.1.156","article-title":"Amikacin therapy for urinary tract infections caused by extended-spectrum \u03b2-lactamase producing Escherichia coli","volume":"31","author":"SY Cho","year":"2016","journal-title":"Korean J Intern Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/IDR.S148703","article-title":"Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli in children","volume":"10","author":"M Polat","year":"2017","journal-title":"Infect Drug Resist"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12916-017-0835-3","article-title":"Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women","volume":"15","author":"C van Nieuwkoop","year":"2017","journal-title":"BMC Med"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"D Moher","year":"2010","journal-title":"BMJ"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000074526","article-title":"Penetration of antimicrobial agents into the prostate","volume":"49","author":"K Charalabopoulos","year":"2003","journal-title":"Chemotherapy"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1086\/652861","article-title":"Treatment of bacterial prostatitis","volume":"50","author":"BA Lipsky","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/aje\/kwh308","article-title":"The epidemiology of acute pyelonephritis in South Korea, 1997\u20131999","volume":"160","author":"M Ki","year":"2004","journal-title":"Am J Epidemiol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","article-title":"If nothing goes wrong, is everything all right? Interpreting zero numerators","volume":"249","author":"JA Hanley","year":"1983","journal-title":"JAMA"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"TF Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref51","unstructured":"Center for Disease Dynamics, Economics & Policy. Antibiotic resistance of Escherichia coli in India. ResistanceMap, Washington DC; 2015 [cited 2018 February 17]. Available from: https:\/\/resistancemap.cddep.org\/CountryPage.php?countryId=17&country=India<\/ext-link>"},{"key":"ref52","first-page":"1221","article-title":"Outpatient parenteral antibiotic therapy (OPAT) in Asia: missing an opportunity","volume":"72","author":"D Fisher","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0197302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T07:32:54Z","timestamp":1589009574000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0197302"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0197302","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,16]]}}}